Spark Holland B.V.and Axel Semrau have announced an expansion of their existing distribution deal to include Switzerland and Austria.
Spark Holland B.V. (Emmen, The Netherlands) and Axel Semrau (Sprockhövel, Germany) have announced an expansion of their existing distribution deal to include Switzerland and Austria. A deal had previously existed between the two companies for five years concerning the distribution of services within Germany.
“We are very pleased to extend the region in which Axel Semrau is our partner. In Germany its team is highly experienced in Spark Holland products. This helps our customers make the right choices in their sample prep challenges,” said Spark President, Rob van der Knaap.
The closer proximity of Axel Samrau to Switzerland and Austria was cited as a major positive in the deal, with improved support and maintenance programmes expected alongside market expansion.
“We can now increase the momentum of Spark’s wellârecognized and market-accepted on-line SPE technology to Swiss and Austrian customers,” said Axel Semrau’s CEO, Dr. Andreas Bruchmann.
For further information, please visit www.sparkholland.com and www.axel-semrau.com
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.